medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 3

<< Back Next >>

Rev Invest Clin 2012; 64 (3)

Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson’s Disease

Cervantes-Arriaga A, Rodríguez-Violante M, Salmerón-Mercado M, Calleja-Castillo J, Corona T, Yescas P, Alonso-Vilatela E

Language: Spanish
References: 20
Page: 220-226
PDF size: 183.00 Kb.


ABSTRACT

Background. Levodopa-induced dyskinesia is one of the main complications and limitations of the treatment of patients with Parkinson’s disease. Objective. To determine the incidence and risk factors involved in the development of dyskinesias in a retrospective cohort of Mexican patients with Parkinson’s disease. Material and methods. We reviewed a total of 601 cases of Parkinson’s disease patients treated at the National Institute of Neurology and Neurosurgery in the period between January 1990 and June 2010; 482 of them had history of exposure to levodopa. Results. The follow-up was equivalent to 4,392 person-years. 154 patients had dyskinesias at some point in the evolution of the disease. The person-time incidence was 35 cases per 1,000 person-years. The onset of motor symptoms before 50 years of age and levodopa doses ≥ 600 mg of levodopa were the main risk factors for early development of dyskinesia (HR of 1.01 [95% CI 1.0 to 1.01, p = 0.001] and HR 1.10 [95% CI 1.04 to 1.23, p = 0.04], respectively]. Conclusion. The main determinants of dyskinesias were present early age of onset of motor symptoms and the dose of levodopa. knowledge of these factors will improve the management planning.


REFERENCES

  1. Jenner P. Molecular mechanisms of L-Dopa-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-77.

  2. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 2007; 21: 677-92.

  3. Calabresi P, Di Fillipo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008; 23: S570-S579.

  4. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-31.

  5. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa- induced dyskinesias in Parkinson’s disease. J Neurol 1999; 246: 1127-33.

  6. Kumar N, Van Gerpen JA, Bower JH, Ajlskog JE. Levodopadyskinesia incidence by age of Parkinson’s disease onset. Mov Disord 2005; 20: 342-4.

  7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.

  8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.

  9. Ahlskog JE, Muenter MD. Frequency of levodopa related dyskinesia and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.

  10. Schrag A, Quinn N. Dyskinesia and motor fluctuations in Parkinson’s disease: a community based study. Brain 2000; 63: 205-9.

  11. Zappia M, Annesi G, Nicoletti G, Arabaia G, Annesi F, Messina D, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson’s disease: an exploratory study. Arch Neurol 2005; 62: 601-05.

  12. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I. Cascade of levodopa dose and weight related dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 2006; 12: 499-505.

  13. Rascol O, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke CE, Lang AE. A five-year study of incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1481-91.

  14. Stowe R, Ives N, Clarke CE, van Hilten JJ, Ferreira J, Hawker RJ, et al. DA therapy in early Parkinson’s disease. Cochrane 2008.

  15. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351: 2498-508.

  16. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008; 15: 493-6.

  17. Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord 2011; 17: 27-9.

  18. Kostic VC, Marinkovic J, Svetel M, Stefanova E, Przeborski S. The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002; 9: 9-14.

  19. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor complications and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756-60.

  20. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with current model. Ann Neurol 2000; 47: S22-S34.




2020     |     www.medigraphic.com